ECSP23070418A - Moduladores de sting (estimulador de genes de interferón) - Google Patents

Moduladores de sting (estimulador de genes de interferón)

Info

Publication number
ECSP23070418A
ECSP23070418A ECSENADI202370418A ECDI202370418A ECSP23070418A EC SP23070418 A ECSP23070418 A EC SP23070418A EC SENADI202370418 A ECSENADI202370418 A EC SENADI202370418A EC DI202370418 A ECDI202370418 A EC DI202370418A EC SP23070418 A ECSP23070418 A EC SP23070418A
Authority
EC
Ecuador
Prior art keywords
stimulator
interferon genes
sting modulators
compounds
sting
Prior art date
Application number
ECSENADI202370418A
Other languages
English (en)
Inventor
Ketan Satish Gajiwala
Eugene Yuanjin Rui
Jianmin Sun
Martin James Wythes
Mehran Jalaie
Ryan Lloyd Patman
Chan Woo Huh
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP23070418A publication Critical patent/ECSP23070418A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de la Fórmula general (I): y sales aceptables desde el punto de vista farmacéutico de estos, procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos y los usos de estos compuestos.
ECSENADI202370418A 2021-03-18 2023-09-15 Moduladores de sting (estimulador de genes de interferón) ECSP23070418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162640P 2021-03-18 2021-03-18
US202163165459P 2021-03-24 2021-03-24

Publications (1)

Publication Number Publication Date
ECSP23070418A true ECSP23070418A (es) 2023-10-31

Family

ID=80819922

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202370418A ECSP23070418A (es) 2021-03-18 2023-09-15 Moduladores de sting (estimulador de genes de interferón)

Country Status (19)

Country Link
US (2) US11964978B2 (es)
EP (1) EP4308563A1 (es)
JP (2) JP7554410B2 (es)
KR (1) KR20230146606A (es)
AU (1) AU2022238001B2 (es)
BR (1) BR112023017731A2 (es)
CA (1) CA3213427A1 (es)
CL (1) CL2023002737A1 (es)
CO (1) CO2023012198A2 (es)
CR (1) CR20230413A (es)
DO (1) DOP2023000194A (es)
EC (1) ECSP23070418A (es)
IL (1) IL306034A (es)
MX (1) MX2023010942A (es)
PE (1) PE20231816A1 (es)
PY (1) PY2219816A (es)
TW (1) TWI829112B (es)
UY (1) UY39676A (es)
WO (1) WO2022195462A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN119212989A (zh) 2022-05-18 2024-12-27 豪夫迈·罗氏有限公司 作为sting激动剂的吡唑衍生物
JP2024041730A (ja) * 2022-09-14 2024-03-27 ファイザー・インク Sting(インターフェロン遺伝子刺激因子)のモジュレーター
WO2025228899A1 (en) * 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) * 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) * 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) * 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) * 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
US20250333398A1 (en) * 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
JP6783312B2 (ja) 2016-01-25 2020-11-11 ファイザー・インク がんを処置するためのox40アゴニストおよび4−1bbアゴニストモノクローナル抗体の組み合わせ
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
CN110016025B (zh) 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
EP3597642A1 (en) * 2018-07-20 2020-01-22 UCB Biopharma SRL Pharmaceutical 6,5 heterobicyclic ring derivatives
JP7104999B2 (ja) 2018-02-21 2022-07-22 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子刺激因子stingのアゴニスト
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
EP3817820A1 (en) 2018-07-03 2021-05-12 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11008344B2 (en) * 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
TWI855000B (zh) 2018-10-11 2024-09-11 日商小野藥品工業股份有限公司 Sting促效化合物
CN113645977A (zh) 2019-03-05 2021-11-12 F-星治疗公司 化合物、组合物和疾病治疗方法
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
MX2022003633A (es) 2019-09-25 2022-04-19 Pfizer Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
CO2023012198A2 (es) 2023-11-30
US11964978B2 (en) 2024-04-23
AU2022238001A1 (en) 2023-09-14
TW202246262A (zh) 2022-12-01
TWI829112B (zh) 2024-01-11
KR20230146606A (ko) 2023-10-19
JP2024164207A (ja) 2024-11-26
JP2024509982A (ja) 2024-03-05
PY2219816A (es) 2022-09-29
CA3213427A1 (en) 2022-09-22
BR112023017731A2 (pt) 2023-10-03
PE20231816A1 (es) 2023-11-16
IL306034A (en) 2023-11-01
US20220306641A1 (en) 2022-09-29
EP4308563A1 (en) 2024-01-24
AU2022238001B2 (en) 2024-11-28
CL2023002737A1 (es) 2024-04-01
CR20230413A (es) 2023-10-13
US20240383903A1 (en) 2024-11-21
DOP2023000194A (es) 2023-11-30
MX2023010942A (es) 2023-09-28
WO2022195462A1 (en) 2022-09-22
JP7554410B2 (ja) 2024-09-20
UY39676A (es) 2022-10-31

Similar Documents

Publication Publication Date Title
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
DOP2024000231A (es) Compuestos y usos de estos
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
CL2020002352A1 (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2024009161A (es) Compuestos de pirrolidina.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
ECSP18056196A (es) Derivados de indano
CL2004000630A1 (es) Compuestos derivados de oxazol; sales de dichos compuestos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que contiene dichos compuestos; y su uso para inhibir el crecimiento tumoral.
AR124720A1 (es) Derivados de pirazolamida
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
MX2024013840A (es) Derivados de pirazina y usos de los mismos
AR129469A1 (es) Inhibidores de rock y sus usos
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR134577A1 (es) Compuestos de bifenilo y fenilpiridina